The short answer
Do not combine an ephedrine-alkaloid-containing Herba Ephedrae product with tranylcypromine. The drug label prohibits sympathomimetic supplements, and oral ephedrine labeling prohibits MAOI co-use. Verify the actual herb, plant part and composition rather than assuming all products called ma huang are identical.
What this answer covers
Oral Herba Ephedrae products consisting of ephedra herb with ephedrine-type alkaloids. The canonical node is kept separate from Ephedra sinica; species, plant part and alkaloid content remain product-specific.
- Supplement or preparation
- Herba Ephedrae
- Medication ingredient
- tranylcypromine
The name alone is incomplete
Herba Ephedrae can describe an ephedra herbal material rather than a single fully specified extract. A pharmacist needs the botanical source, plant part, preparation and ingredient list to understand the exposure.
Why ephedrine content changes the answer
The label for tranylcypromine prohibits supplements with sympathomimetic effects. Ephedrine-containing ephedra herb fits the constituent-level concern; an unclear or incomplete label does not establish an absence of those alkaloids.
A timing gap is not protection
Oral ephedrine labeling prohibits use with an MAOI and for two weeks after stopping one. Do not discontinue tranylcypromine to start the herb yourself. Medication changes need the prescriber's plan.
What this article does not prove
No controlled study of this exact herb preparation with tranylcypromine was found. The recommendation uses explicit drug warnings and botanical chemistry. Serious headache, chest pain or severe blood-pressure symptoms require urgent medical care.
Evidence and practical considerations
Side effects & toxicity
PARNATE contraindicates sympathomimetic dietary supplements. Ephedrine oral labeling prohibits MAOI use. The herb-level inference applies only when the preparation supplies those alkaloids.
- Exact scope
- Oral Herba Ephedrae products consisting of ephedra herb with ephedrine-type alkaloids. The canonical node is kept separate from Ephedra sinica; species, plant part and alkaloid content remain product-specific. with Oral tranylcypromine tablets; current sulfate-tablet labeling uses the named active ingredient.
- Medication form and route
- oral
What remains uncertain
- No exact Herba Ephedrae-tranylcypromine trial was identified. The database name does not establish a botanical species or amount; it is not merged with a single-species node.
Factors that may matter: Exact supplement preparation and complete concomitant-medication list require assessment..
Read the supporting source summaries
Source 1: Current U.S. prescribing information
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: Patients prescribed oral tranylcypromine sulfate tablets.
The label contraindicates sympathomimetic supplements, hydroxytryptophan, tryptophan and SAM-e; it names St. John's wort in the serotonin-syndrome warning and lists excessive caffeine among exposures to avoid.
How this applies: Primary authority for exact tranylcypromine tablet precautions. Named supplements and class-based applications are kept distinct.
A labeled contraindication is not a measurement of the frequency of an event with each product; L-tyrosine and Panax ginseng are not individually named.
Source 2: U.S. oral-product labeling
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: Users of the labeled oral ephedrine hydrochloride product.
Do not use during prescription MAOI treatment or for two weeks after stopping an MAOI. The label also warns about blood-pressure and heart-rate increases.
How this applies: Constituent-level warning applicable to ephedrine-containing ephedra preparations; no botanical coadministration trial is claimed.
The source concerns a specific ephedrine salt and product. The botanical bridge depends on actual ephedrine-alkaloid content, not shared wording alone.
Source 3: Federal botanical evidence summary
ods.od.nih.gov · Source check Sep 10, 2026
Population: Botanical and clinical literature summarized by NIH; not patients receiving the exact MAOI pair.
The source identifies ephedrine and related adrenergic alkaloids in stems and distinguishes ephedra species.
How this applies: Historical fact sheet contains outdated marketing context. Used only for plant/part/constituent information, not current regulatory status or exact-pair outcome rates.
Historical fact sheet contains outdated marketing context. Used only for plant/part/constituent information, not current regulatory status or exact-pair outcome rates.
Source 4: Federal safety information
nccih.nih.gov · Source check Sep 10, 2026
Population: Users of ephedra-containing products.
NCCIH describes serious cardiovascular and neurologic risks and the FDA prohibition on ephedrine alkaloids in dietary supplements.
How this applies: Does not establish a measured interaction rate with phenelzine or tranylcypromine. Does not cover every ephedra species or plant part.
Does not establish a measured interaction rate with phenelzine or tranylcypromine. Does not cover every ephedra species or plant part.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Article prepared | |
| Initial targeted research draft. Inspected source material, adjudicated the current checker statements, and recorded preparation limits. Clinical review has not occurred. | |
| Research summary published |
Article revision: 2c620b92d6d22dd3
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.